Next pandemic could be more lethal than Covid, says Oxford vaccine creator

Sarah Gilbert stressed on the need for more funding on pandemic preparedness

A health worker testing for Covid-19 collects the swab sample of a man at a railway station in Ranchi on November 27, 2021. (PTI Photo)
A health worker testing for Covid-19 collects the swab sample of a man at a railway station in Ranchi on November 27, 2021. (PTI Photo)
IANS
2 min read Last Updated : Dec 06 2021 | 2:55 PM IST
While the Covid-19 crisis is not over yet with the new super mutant Omicron spreading to 38 countries, the next pandemic could be even more lethal, said the creator of the Oxford/AstraZeneca vaccine Professor Sarah Gilbert.

Delivering the 44th Richard Dimbleby Lecture, Gilbert cautioned that it is increasingly obvious that "this pandemic is not done with us", and vaccines could also prove to be less effective against the Omicron variant, the BBC reported.

Gilbert, a professor of vaccinology at the University of Oxford whose team developed the Covid vaccine now used in 170 countries, said the scientific advances made and knowledge gained in research fighting against the coronavirus must not be lost.

She also stressed on the need for more funding on pandemic preparedness.

"This will not be the last time a virus threatens our lives and our livelihoods. The truth is, the next one could be worse. It could be more contagious, or more lethal, or both," Gilbert was quoted as saying.

"We cannot allow a situation where we have gone through all we have gone through, and then find that the enormous economic losses we have sustained mean that there is still no funding for pandemic preparedness."

"All the advances we have made, and the knowledge we have gained, must not be lost," she said.

So far it is known that the Omicron variant's spike protein contained mutations known to increase the transmissibility of the virus.

"But there are additional changes that may mean antibodies induced by the vaccines, or by infection with other variants, may be less effective at preventing infection with Omicron."

Moreover, Omicron is said to appear less dangerous than previous variants like Delta, which has claimed more than 5 million lives, so far.

However, Gilbert said reduced protection against infection and mild disease would not necessarily mean reduced protection against severe illness and death.

"Until we know more, we should be cautious, and take steps to slow down the spread of this new variant."

The UK recorded 86 new cases of the Omicron variant on Sunday, taking the total so far to 246. In total, 43,992 cases and 54 deaths within 28 days of a positive coronavirus test were recorded on Sunday.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story